About ZENBEXUS (iberdomide)
ZENBEXUS is indicated - in combination with daratumumab and hyaluronidase-fihj and dexamethasone, for the treatment of adult patients with multiple myeloma who have received at least one prior line of therapy including a proteasome inhibitor and an immunomodulatory agent. This indication is approved under accelerated approval based on MRD-negative complete response at any time; continued approval may be contingent upon verification of clinical benefit in confirmatory trials. ZENBEXUS carries a Boxed Warning for embryo-fetal toxicity and serious venous and arterial thromboembolism and is available only through the ZENBEXUS REMS program. Full prescribing information, including additional warnings and precautions, is available from Bristol Myers Squibb.
About Hematogenix
Hematogenix is a global specialty oncology and hematopathology reference laboratory and contract research organization. Hematogenix operates , CAP-accredited and CLIA certified laboratories in the United States, United Kingdom, Malaysia, and China, supporting major pharmaceutical sponsors across Phase 2 and Phase 3 registrational studies with specialized diagnostic and biomarker assay capabilities.
ZENBEXUS is a trademark of Bristol Myers Squibb.
This release describes an assay methodology cited in the FDA-approved prescribing information for ZENBEXUS (iberdomide). It does not constitute an endorsement by Bristol Myers Squibb, and all clinical data regarding ZENBEXUS, including safety and efficacy information, should be referenced from the official prescribing information.
(C) 2026 Electronic News Publishing, source ENP Newswire